DSIP (Delta Sleep-Inducing Peptide): Does It Help Sleep?

DSIP — delta sleep-inducing peptide — carries its claim right in its name. It was first isolated in 1974 by the Swiss Schoenenberger–Monnier group, who recovered it from the cerebral venous blood of rabbits induced into a state of sleep. The early hope was that here, at last, was an endogenous sleep substance you could give to people to induce deep, delta-wave sleep. It’s a clean, appealing story. The awkward part is that, half a century on, the human evidence has never really lived up to the name.

Researcher in a laboratory analyzing samples for a scientific study

A long history, a thin result

The name comes from animal work: infused into the rabbit brain, the peptide induced spindle and delta EEG activity and reduced motor movement. Translating that to humans has been far less convincing. The literature is a patchwork of small studies with mixed and often unimpressive results, and some investigations on sleep architecture found only minor effects or no correlation at all.

One of the more cited early human studies tested synthetic DSIP in just six normal volunteers in a double-blind crossover design, infusing it intravenously in the morning; the subjects reported increased sleep in the period after dosing. But a sample of six, in one lab, is the kind of result that generates hypotheses, not recommendations — and studies of DSIP for insomnia have produced conflicting outcomes rather than a consistent benefit.

Despite a fifty-year head start, DSIP lacks robust, replicated, modern human trials. The sleep evidence is weak and conflicting — not absent, but nowhere near strong enough to act on.

Person napping peacefully in daylight, illustrating natural rest and sleep

Where things actually stand

Discovered 1974 in rabbit blood; the original delta/spindle EEG effect was an animal finding.
Human sleep and insomnia studies are small, old, and contradictory.
No large, modern, controlled trials establish a reliable sleep benefit in people.
Long-term safety and side effects of DSIP use have not been established in clinical research, and it is not an approved drug.

Medical laboratory professional examining test tubes and samples

Fifty years of evidence, summarised

Finding	Species	Year	What it establishes
Delta/spindle EEG activity, reduced movement	Rabbit	1974 onward	The name — and an animal effect
Blood-brain barrier transport	Rabbit	1977	It reaches the brain in animals
Sequence and synthesis characterised	—	1978	Real, well-defined chemistry
Effects on human sleep behaviour	Human	1981	6 volunteers, crossover; small and contradictory
Any modern controlled human trial	Human	—	None

Fifty years is long enough that the absence in the last row is the finding. A compound that was sequenced in 1978 and still has no modern controlled sleep trial has not been overlooked — it has been tried and has not produced a result worth pursuing.

What the FDA says

Reviewing DSIP — listed as emideltide — for compounding, the agency states it “has not identified safety-related information regarding emideltide for the proposed route of administration” and therefore “lacks sufficient information to know whether the drug would cause harm if administered to humans.”

How to read the marketing

When DSIP is sold as a sleep aid, the strongest pitch is its name and its age — “it’s been studied for decades.” But longevity of study is not the same as strength of result. In DSIP’s case the long history mostly tells us the promised effect kept failing to show up robustly in humans. That’s exactly the context the marketing tends to omit.

Frequently asked questions

What is DSIP?

Delta sleep-inducing peptide, a nonapeptide first isolated in 1974 from rabbit blood by the Swiss Schoenenberger–Monnier group. The name comes from the animal finding that infusing it into the rabbit brain produced delta and spindle EEG activity.

Does DSIP actually work for sleep?

There is no modern controlled human trial establishing that it does. The most-cited human study tested synthetic DSIP in six volunteers in a double-blind crossover design; the human literature overall is small, old, and contradictory.

Is DSIP safe?

Unknown. The FDA states it has not identified safety-related information for the proposed route and lacks sufficient information to know whether it would cause harm in humans. Long-term safety has never been characterised.

Is DSIP FDA approved?

No. It is not an approved drug, and it appears on the FDA’s list of bulk substances that may present significant safety risks in compounding.

Why is DSIP still sold if it doesn’t have evidence?

Because its strongest selling points are its name and its age — “studied since the 1970s” sounds like accumulated evidence when it actually describes a long absence of it. A name that asserts the effect is doing marketing work that the trials never did.

Is DSIP better than melatonin for sleep?

Melatonin has a far larger human evidence base, including trials that measured sleep outcomes directly — see melatonin for sleep. That is a low bar DSIP does not clear, since it has no modern controlled trial at all.

The takeaway

DSIP is a genuinely intriguing piece of neurobiology with a name that overpromises. If you’re after better sleep, the honest assessment is that the human evidence for DSIP is too weak and inconsistent to recommend it, and far better-supported levers — sleep timing, light exposure, and addressing the obvious disruptors — deserve attention first. The name is a hypothesis, not a verdict.